Biohaven's Opakalim Shows Strong Seizure Control in Epilepsy Data, Prolonging Time to Second Seizure to 141 Days
BHVN sits 27% above its 52-week low of $7.48.
Summary
Biohaven announced positive new clinical data for its drug Opakalim in epilepsy, showing it significantly prolonged the median time to a second seizure to 141 days, compared to 47 days for placebo. This data also highlighted a favorable tolerability profile. This is a material positive development for Opakalim, especially following its prior late-stage clinical trial failures in MDD and bipolar disorder as disclosed in the March 2, 2026 10-K. Investors will now watch for top-line Phase 2/3 results in refractory focal epilepsy, expected in the second half of 2026.
At the time of this announcement, BHVN was trading at $9.49 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $7.48 to $18.57. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.